Loap Pierre, Goudjil Farid, Servois Vincent, Kirov Krassen, Fourquet Alain, Kirova Youlia
Department of Radiation Oncology, Institut Curie, Paris, France.
Department of Radiology, Institut Curie, Paris, France.
Int J Part Ther. 2023 Mar 9;10(1):59-64. doi: 10.14338/IJPT-22-00038.1. eCollection 2023 Summer.
The exposition of cardiac conduction system during breast radiation therapy has never been studied, despite the increasing use of intensity-modulated radiation therapy, which exposes larger volume to low-dose bath. We evaluated conduction node exposure during breast irradiation with volumetric modulated arc therapy and estimated the potential dosimetric benefit with intensity-modulated proton therapy.
Atrioventricular (AVN) and sinoatrial (SAN) nodes were retrospectively delineated according to published guidelines on the simulation computed tomography scans of 12 breast cancer patients having undergone conserving surgery and adjuvant locoregional volumetric modulated arc therapy. Intensity-modulated proton therapy treatment was replanned on the simulation computed tomography scans for all breast cancer patients. Mean and maximum doses delivered to the SAN and the AVN were retrieved and compared. Correlation coefficients were calculated between doses to the SAN or the AVN and the whole heart.
Average mean doses delivered to the SAN and AVN were 2.8 and 2.3 Gy, respectively, for left-sided irradiation and 9.6 and 3.6 Gy, respectively, for right-sided irradiation. Average maximum doses to the SAN and AVN were 3.5 Gy and 2.8 Gy, respectively, for left-sided irradiation and 13.1 and 4.6 Gy, respectively, for right-sided irradiation. Intensity-modulated proton therapy significantly reduced mean and maximum doses to the SAN and AVN. Correlations between doses to the SAN or AVN and whole heart were usually significant.
SAN and AVN can be substantially exposed during breast volumetric modulated arc therapy, especially for right-sided irradiation. Cardiotoxicity studies evaluating conduction node exposure might define dose constraints and criteria for additional cardiac-sparing techniques, such as respiratory techniques or proton therapy, which could benefit patients with underlying rhythmic or conduction disorders.
尽管调强放射治疗的使用日益增加,使得更大体积的组织暴露于低剂量照射中,但乳房放射治疗期间心脏传导系统的受照情况从未被研究过。我们评估了容积调强弧形放疗期间心脏传导节点的受照情况,并估计了调强质子治疗潜在的剂量学益处。
根据已发表的指南,对12例接受保乳手术及辅助局部区域容积调强弧形放疗的乳腺癌患者的模拟计算机断层扫描图像进行回顾性分析,勾画出房室结(AVN)和窦房结(SAN)。对所有乳腺癌患者的模拟计算机断层扫描图像重新进行调强质子治疗计划。获取并比较输送至SAN和AVN的平均剂量和最大剂量。计算输送至SAN或AVN的剂量与全心剂量之间的相关系数。
左侧照射时,输送至SAN和AVN的平均平均剂量分别为2.8 Gy和2.3 Gy,右侧照射时分别为9.6 Gy和3.6 Gy。左侧照射时,SAN和AVN的平均最大剂量分别为3.5 Gy和2.8 Gy,右侧照射时分别为13.1 Gy和4.6 Gy。调强质子治疗显著降低了输送至SAN和AVN的平均剂量和最大剂量。输送至SAN或AVN的剂量与全心剂量之间的相关性通常具有显著性。
在乳房容积调强弧形放疗期间,SAN和AVN可能会受到显著照射,尤其是右侧照射时。评估传导节点受照情况的心脏毒性研究可能会确定剂量限制以及其他心脏保护技术(如呼吸技术或质子治疗)的标准,这可能会使患有潜在节律或传导障碍的患者受益。